fashion -WSS

fashion

author：fashion 2025-09-29 14:00:30 - browse：613

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： NYU radiologists take on the challenge of expensive MRI machines

hotspot

focus

WSS

Morphosys mixed study results for blood cancer drug

Does good food count as health care? Study aims to find out

Childhood cancer progress stalls for Black, Hispanic kids: Report

Congress: Eradicate hepatitis C and reduce the deficit

Woman gored by Bison at Yellowstone

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

knowledge

fashion

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Who gets to use the title 'doctor'?

The cancer drug shortage isn’t new — and neither are the solutions

In key trial, Verve's treatment lowers cholesterol levels in patients

Virginia high school admissions case could be legal follow

Congress likely to miss an opportunity to fix drug shortages issue

What does generative AI mean for health care? We asked experts

Involuntary treatment for addiction doesn't work

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eli Lilly to acquire Versanis in heated race for weight loss drugs

focus

Readout LOUD podcast: A CRISPR milestone, biotech mixology

PBM reforms clear House panel

Morphosys mixed study results for blood cancer drug

FDA's Woodcock to retire early next year

Global childhood vaccinations edge closer to pre

Woman gored by Bison at Yellowstone

focus

hotspot

focus

Wikipedia